Lysergic Acid Diethylamide and Psilocybin for the Management of Patients with Persistent Pain: a Potential Role?
- 3 May 2018
- journal article
- review article
- Published by Taylor & Francis in Pain Management
- Vol. 8 (3) , 217-229
Abstract
Recently, there has been interest in lysergic acid diethylamide (LSD) and psilocybin for depression, anxiety and fear of death in terminal illness. The aim of this review is to discuss the potential use of LSD and psilocybin for patients with persistent pain. LSD and psilocybin are 5-hydroxytryptamine receptor agonists and may interact with nociceptive and antinociceptive processing. Tentative evidence from a systematic review suggests that LSD (7 studies, 323 participants) and psilocybin (3 studies, 92 participants) may be beneficial for depression and anxiety associated with distress in life-threatening diseases. LSD and psilocybin are generally safe if administered by a healthcare professional, although further investigations are needed to assess their utility for patients with persistent pain, especially associated with terminal illness.Keywords
This publication has 95 references indexed in Scilit:
- Psychedelics and Mental Health: A Population StudyPLOS ONE, 2013
- Pain relief produces negative reinforcement through activation of mesolimbic reward–valuation circuitryProceedings of the National Academy of Sciences, 2012
- Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteersDrug and Alcohol Dependence, 2012
- Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trialsJournal of Psychopharmacology, 2012
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybinProceedings of the National Academy of Sciences, 2012
- The Cortical Rhythms of Chronic Back PainThe Journal of Neuroscience, 2011
- Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature UpdateMayo Clinic Proceedings, 2010
- How do you feel — now? The anterior insula and human awarenessNature Reviews Neuroscience, 2009
- Human hallucinogen research: guidelines for safetyJournal of Psychopharmacology, 2008
- TNF‐mediated inflammatory diseaseThe Journal of Pathology, 2007